In brief
BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3607 (Published 04 June 2013) Cite this as: BMJ 2013;346:f3607Prolonged tamoxifen offers benefits: Women with oestrogen positive breast cancer benefit from taking tamoxifen for more than five years, and the advantages increase over time, a study has found.1 Tamoxifen reduced the risk of a recurrence of breast cancer after nine years (580 of 3468 women who took tamoxifen for more than five years versus 672 of 3485 women who stopped tamoxifen at five years; P<0.01), with a rate ratio of 0.75 (95% confidence interval 0.66 to 0.86). Longer treatment also reduced breast cancer mortality (392 versus 443 deaths after recurrence; P=0.05), with a rate ratio after nine years of 0.86 (0.75 to 0.97). More …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.